{"schema_version":"1.0","type":"article","title":"減重針降價，禮來營收增39%甩開諾和","url":"https://drugnews.com.tw/articles/2026-11-02-lilly-q3-2026-glp1-price-cut-volume-novo.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-02-lilly-q3-2026-glp1-price-cut-volume-novo.md","lang":"zh-Hant","date":"2026-11-02","publish_at":"2026-11-02T08:00:00+08:00","updated_at":"2026-11-02","category":"製藥巨頭系列","topic":"製藥巨頭系列","tags":["禮來","諾和諾德","減重藥","Mounjaro","財報"],"summary":"禮來第三季實收價格跌15%、量增53%，營收243.97億美元年增39%，全年指引上修到910–920億美元；諾和諾德同樣降價卻預估全年銷售持平到衰退6%。降價打開新病人，產能決定誰接得住。","key_points":["禮來 2027 年初給出的全年營收指引中點會站上 1,000 億美元：2026 年第三季實收價格跌 15%、量增 53%，營收 243.97 億美元、年增 39%。","禮來 2026 年 10 月 29 日把全年營收指引從 850–870 億美元上修到 910–920 億美元；諾和諾德 2026 年 8 月 4 日的全年調整後銷售指引為 0% 到負 6%。","Mounjaro 2026 年第三季營收 107.23 億美元、年增 65%，其中美國以外 57 億美元、年增 93%，已超過美國本土的 50 億美元。"],"facts":[{"claim":"禮來 2026 Q3 營收","value":24397,"unit":"百萬美元","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"禮來 2026 Q3 營收年增率","value":39,"unit":"%","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"禮來 2026 Q3 全球量變化","value":53,"unit":"%","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"禮來 2026 Q3 全球實收價格變化","value":-15,"unit":"%","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"禮來 2026 Q3 美國營收","value":15.1,"unit":"十億美元","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"禮來 2026 Q3 美國實收價格變化","value":-7,"unit":"%","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"禮來 2026 Q3 美國以外實收價格變化","value":-29,"unit":"%","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"禮來 2026 Q3 美國以外量變化","value":76,"unit":"%","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"Mounjaro 2026 Q3 全球營收","value":10723,"unit":"百萬美元","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"Mounjaro 2026 Q3 美國以外營收","value":5.7,"unit":"十億美元","as_of":"2026-10-29","source":"https://www.stocktitan.net/news/LLY/lilly-reports-third-quarter-2026-financial-results-raises-full-year-6pqpbpd0gw14.html"},{"claim":"Zepbound 2026 Q3 全球營收","value":5352,"unit":"百萬美元","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"Foundayo 2026 Q3 營收","value":184,"unit":"百萬美元","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"禮來 2026 Q3 毛利率（報告）","value":83.9,"unit":"%","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"禮來 2026 全年營收指引（上修後）","value":"910–920","unit":"億美元","as_of":"2026-10-29","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"claim":"禮來 2026 Q3 收購研發費用","value":4181,"unit":"百萬美元","as_of":"2026-10-29","source":"https://www.stocktitan.net/news/LLY/lilly-reports-third-quarter-2026-financial-results-raises-full-year-6pqpbpd0gw14.html"},{"claim":"Medicare GLP-1 過渡方案領禮來處方人數（7/1 起）","value":"超過 50 萬","unit":"人","as_of":"2026-10-29","source":"https://www.fool.com/earnings/call-transcripts/2026/10/29/eli-lilly-lly-q3-2026-earnings-call-transcript/"},{"claim":"禮來 2026 一次性收入（明年不再）","value":20,"unit":"億美元","as_of":"2026-10-29","source":"https://www.fool.com/earnings/call-transcripts/2026/10/29/eli-lilly-lly-q3-2026-earnings-call-transcript/"},{"claim":"Mounjaro 2025 Q3 全球營收","value":6.52,"unit":"十億美元","as_of":"2025-10-30","source":"https://www.americanpharmaceuticalreview.com/1315-News/622437-Lilly-Delivers-Record-Q3-Results-Raises-Full-Year-Guidance-Amid-R-D-Pipeline-Momentum/"},{"claim":"Wegovy 口服錠 2026 Q2 銷售","value":3218,"unit":"百萬丹麥克朗","as_of":"2026-08-04","source":"https://ml-eu.globenewswire.com/Resource/Download/59861be7-056f-420d-985b-a7e976f8426d"},{"claim":"諾和諾德 2026 調整後銷售成長指引","value":"0 至 -6","unit":"%（固定匯率）","as_of":"2026-08-04","source":"https://ml-eu.globenewswire.com/Resource/Download/59861be7-056f-420d-985b-a7e976f8426d"},{"claim":"美國 Wegovy 注射劑 2026 Q2 銷售變化（固定匯率）","value":-22,"unit":"%","as_of":"2026-08-04","source":"https://ml-eu.globenewswire.com/Resource/Download/59861be7-056f-420d-985b-a7e976f8426d"},{"claim":"Wegovy 2027-01-01 美國定價調降幅度","value":50,"unit":"%（約）","as_of":"2026-08-04","source":"https://ml-eu.globenewswire.com/Resource/Download/59861be7-056f-420d-985b-a7e976f8426d"},{"claim":"Wegovy 口服錠美國累計處方","value":500,"unit":"萬張以上","as_of":"2026-08-04","source":"https://glp1-us.com/news/2026-08-04-novo-q2-wegovy-pill-5m-prescriptions/"},{"claim":"Foundayo FDA 核准日","value":"2026-04-01","unit":"日期","as_of":"2026-04-01","source":"https://www.biopharmadive.com/news/fda-approves-lilly-obesity-pill-orforglipron-foundayo-novo/816359/"},{"claim":"禮來 2026 Q3 美國以外腸泌素市場占有率","value":58,"unit":"%（約）","as_of":"2026-10-29","source":"https://www.fool.com/earnings/call-transcripts/2026/10/29/eli-lilly-lly-q3-2026-earnings-call-transcript/"}],"sections":["01｜價格跌 15%，營收怎麼還多 39%","02｜多出來的病人從哪裡來","03｜諾和諾德贏了藥丸，輸了總帳","04｜1,000 億美元差在哪裡","參考資料"],"references":[{"title":"Lilly reports third-quarter 2026 financial results, raises full-year guidance","source":"Eli Lilly","date":"2026-10-29","url":"https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full"},{"title":"Lilly Q3 earnings: revenue rises 39% to $24.4B（新聞稿全文與附表","source":"Stock Titan","date":"2026-10-29","url":"https://www.stocktitan.net/news/LLY/lilly-reports-third-quarter-2026-financial-results-raises-full-year-6pqpbpd0gw14.html"},{"title":"Eli Lilly (LLY) Q3 2026 Earnings Call Transcript","source":"The Motley Fool","date":"2026-10-29","url":"https://www.fool.com/earnings/call-transcripts/2026/10/29/eli-lilly-lly-q3-2026-earnings-call-transcript/"},{"title":"Lilly Delivers Record Q3 Results, Raises Full-Year Guidance（2025 年第三季","source":"American Pharmaceutical Review","date":"2025-10-30","url":"https://www.americanpharmaceuticalreview.com/1315-News/622437-Lilly-Delivers-Record-Q3-Results-Raises-Full-Year-Guidance-Amid-R-D-Pipeline-Momentum/"},{"title":"Financial report for the period 1 January 2026 to 30 June 2026","source":"Novo Nordisk","date":"2026-08-04","url":"https://ml-eu.globenewswire.com/Resource/Download/59861be7-056f-420d-985b-a7e976f8426d"},{"title":"Novo Nordisk Q2: Wegovy pill tops 5M US prescriptions","source":"GLP-1 US","date":"2026-08-04","url":"https://glp1-us.com/news/2026-08-04-novo-q2-wegovy-pill-5m-prescriptions/"},{"title":"FDA approves Lilly obesity pill, triggering battle with Novo Nordisk","source":"BioPharma Dive","date":"2026-04-01","url":"https://www.biopharmadive.com/news/fda-approves-lilly-obesity-pill-orforglipron-foundayo-novo/816359/"},{"title":"韓美半價減肥針開戰 Mounjaro，先痛的是 Wegovy","source":"藥時事","date":"2026-10-20","url":"https://drugnews.com.tw/articles/2026-10-20-korea-glp1-price-war-hanmi-eppe-novo.html"},{"title":"瘦瘦針的雙藥賭注","source":"藥時事","date":"2026-10-14","url":"https://drugnews.com.tw/articles/2026-10-14-eloratzp-weight-loss-tolerability-persistence.html"},{"title":"減肥藥還是太強了，禮來 猛健樂 賺爛！","source":"藥時事","date":"2026-05-08","url":"https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth.html"}],"images":[{"alt":"圖4｜降價怎麼變成量：從低價入口到新病人","url":"https://drugnews.com.tw/assets/articles/lilly-q3-2026-glp1-price-cut-volume-novo/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/lilly-q3-2026-glp1-price-cut-volume-novo/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-02）。減重針降價，禮來營收增39%甩開諾和。https://drugnews.com.tw/articles/2026-11-02-lilly-q3-2026-glp1-price-cut-volume-novo.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}